These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24976315)

  • 21. A divided INN crowd.
    Eich G
    Nat Biotechnol; 2014 Feb; 32(2):131. PubMed ID: 24509754
    [No Abstract]   [Full Text] [Related]  

  • 22. A divided INN crowd.
    Greenwood J
    Nat Biotechnol; 2014 Feb; 32(2):131-2. PubMed ID: 24509753
    [No Abstract]   [Full Text] [Related]  

  • 23. A divided INN crowd.
    Chin WW
    Nat Biotechnol; 2014 Feb; 32(2):130. PubMed ID: 24509752
    [No Abstract]   [Full Text] [Related]  

  • 24. [Do health services benefit from exchange of preparations in pharmacies?].
    Ekholm ML
    Lakartidningen; 2007 Nov 14-20; 104(46):3476. PubMed ID: 18074614
    [No Abstract]   [Full Text] [Related]  

  • 25. Biosimilars and safety issues.
    Dammacco F; Abbracchio MP; Gesualdo L; Goffredo F; Ronco C; Zanella A
    Leuk Lymphoma; 2009 Apr; 50(4):656-8. PubMed ID: 19373667
    [No Abstract]   [Full Text] [Related]  

  • 26. Biosimilars: considerations for an abbreviated pathway.
    Kozlowski S; Behrman R
    Leuk Lymphoma; 2009 Apr; 50(4):527-8. PubMed ID: 19373649
    [No Abstract]   [Full Text] [Related]  

  • 27. Recent China Food and Drug Administration reform: impact on the present and future of bioanalytical contract research organization laboratories in China.
    Meng M
    Bioanalysis; 2017 Sep; 9(17):1285-1288. PubMed ID: 28901171
    [No Abstract]   [Full Text] [Related]  

  • 28. Indian generic drug production. Benefits of EU-India free trade agreement.
    Ager B
    BMJ; 2011 Apr; 342():d2439. PubMed ID: 21502277
    [No Abstract]   [Full Text] [Related]  

  • 29. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 30. Quality by design: concepts for ANDAs.
    Lionberger RA; Lee SL; Lee L; Raw A; Yu LX
    AAPS J; 2008 Jun; 10(2):268-76. PubMed ID: 18465252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The rise of foreign agents. Drugs and other medical products from offshore suppliers can offer tremendous savings, but safety has become an increasing concern.
    Rhea S
    Mod Healthc; 2008 May; 38(21):28-30. PubMed ID: 18711901
    [No Abstract]   [Full Text] [Related]  

  • 32. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
    Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
    Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Manufacturer recalls commonly used painkiller amid fears of possible sabotage.
    Ginn S
    BMJ; 2011 Sep; 343():d5628. PubMed ID: 21893567
    [No Abstract]   [Full Text] [Related]  

  • 34. A survey of the quality of generic clarithromycin products manufactured in Slovenia and Israel.
    Nightingale CH
    Adv Ther; 2000; 17(3):167-78. PubMed ID: 11183454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Generics: similarities, bioequivalence but no conformity].
    Even-Adin D; De Muylder JA; Sternon J
    J Pharm Belg; 2002; 57(1):14-20. PubMed ID: 11913095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Issues in Indian science.
    Byravan S
    Science; 2005 Jul; 309(5734):557-8; author reply 557-8. PubMed ID: 16044529
    [No Abstract]   [Full Text] [Related]  

  • 37. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Equivocal role of micelles in Eprex adverse events.
    Smiell JM
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595347
    [No Abstract]   [Full Text] [Related]  

  • 39. Equivocal role of micelles in Eprex adverse events.
    Schellekens H; Crommelin DJ
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595346
    [No Abstract]   [Full Text] [Related]  

  • 40. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.